Fusion Pharmaceuticals Inc. (FUSN) Tops Q2 EPS by 1c

Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) reported Q2 EPS of ($0.38), $0.01 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $34 thousand versus the consensus estimate of $84.38 thousand.

For earnings history and earnings-related data on Fusion Pharmaceuticals Inc. (FUSN) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
• Viking Holdings Ltd (VIK) Tops Q2 EPS by 36c